Tiziana Life Sciences Ltd (TLSA) stock
TLSANasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.81+0.16 (+24.75%)
Close on Nov 18, 2026Market cap $97.42MP/E –Yield –
Tiziana Life Sciences operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
For fiscal 2025 it was -$21.13M. The highest annual figure on record is -$9.87M in fiscal 2018.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$21.13M | – |
| FY2024 | Dec 31, 2024 | -$15.79M | – |
| FY2023 | Dec 31, 2023 | -$17.98M | – |
| FY2022 | Dec 31, 2022 | -$14.59M | – |
| FY2021 | Dec 31, 2021 | -$27.37M | – |
| FY2020 | Dec 31, 2020 | -$28.03M | – |
| FY2019 | Dec 31, 2019 | -$9.92M | – |
| FY2018 | Dec 31, 2018 | -$9.87M | – |
| FY2017 | Dec 31, 2017 | -$10.49M | – |
| FY2016 | Dec 31, 2016 | -$9.88M | – |
See a number that looks wrong?